Neurotoxicity evoked by organophosphates and available countermeasures

Lenka Pulkrabkova1,2, Barbora Svobodova1,2, Jan Konecny1,2

  • 1Faculty of Military Health Sciences, University of Defence, Trebesska 1575, Hradec Kralove, Czech Republic.

Archives of Toxicology
|November 6, 2022
PubMed

Insights

Organophosphate poisoning causes severe neurotoxicity by inhibiting acetylcholinesterase. Targeting glutamatergic cascades, rather than reactive oxygen species, offers a promising neuroprotection strategy against lasting nerve damage.

Area of Science:

  • Neuroscience
  • Toxicology
  • Pharmacology

Background:

  • Organophosphorus (OP) compounds cause significant acute and chronic neurotoxicity.
  • Current treatments lack efficacy in preventing OP-induced nerve damage.
  • OP toxicity stems from acetylcholinesterase inhibition, leading to excitotoxicity and neuroinflammation.

Purpose of the Study:

  • To review and present neuroprotection strategies against organophosphate toxicity.
  • To identify effective therapeutic targets for mitigating OP-induced neurological damage.
  • To evaluate current and potential interventions for organophosphate poisoning.

Main Methods:

  • Review of existing literature on organophosphate neurotoxicity mechanisms.
  • Analysis of neuroprotection strategies targeting cholinergic and glutamatergic systems.
  • Evaluation of the efficacy of antioxidants and anti-inflammatory agents.

Main Results:

  • Organophosphate toxicity involves acetylcholinesterase inhibition, acetylcholine accumulation, and subsequent glutamatergic excitotoxicity.
  • Targeting glutamatergic pathways, particularly with agents like tezampanel and caramiphen, shows promise.
  • Strategies focusing on reactive oxygen species (ROS) and neuroinflammation have yielded less productive results.

Conclusions:

  • No single antidote effectively protects against all organophosphate toxic effects.
  • Early intervention targeting key neurotoxic pathways, especially glutamatergic cascades, is crucial for neuroprotection.
  • Antagonizing glutamatergic hyperactivity presents a more efficacious approach than current GABAergic strategies for OP-induced seizures and brain protection.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
968
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.1K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
906
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
635
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
750